Eye surgery showdown: which fix for nearsightedness wins?
NCT ID NCT07291986
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study compared two common surgeries for moderate nearsightedness: FemtoLasik and implantable collamer lens (ICL) implantation. Researchers looked at how stable the vision correction was, contrast sensitivity, and higher-order aberrations in 60 adults aged 21-40. The goal was to see which procedure offers better visual outcomes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors choose the best surgical option for treating moderate nearsightedness.
- What could go wrong
- This is a small, completed study with only 60 participants, so results may not apply to everyone. Both procedures carry standard surgical risks like infection or under-correction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Jan 2023
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Group I - FemtoLASIK subgroup: * Age range: 21-40 years. * Stable myopia for at least one year (refractive change ≤ 0.50 D). * Spherical equivalent between -4.00 D and -8.00 D. * Corneal thickness ≥ 500 μm, residual stromal bed \> 300 μm and percentage of tissue altered \< 39%. * No evidence of keratoconus or ectatic changes on corneal topography/tomography. * Mesopic pupil diameter ≤ 6.5 mm. * Absence of ocular surface disease or significant dry eye symptoms. * No history of prior ocular surgery or trauma. Group II - ICL subgroup: * Age range: 21-40 years. * Stable myopia (with or without astigmatism) for ≥1 year. * Spherical equivalent between -4.00 D and -8.00 D. * Anterior chamber depth ≥ 2.8 mm from endothelium. * Endothelial cell density ≥ 2500 cells/mm². * White-to-white and sulcus-to-sulcus diameters suitable for ICL sizing. * Clear crystalline lens with no signs of early cataract. * No history of intraocular surgery, uveitis, or glaucoma. Exclusion Criteria: Patients with mild myopia (\<-4D) or high myopia (\>- 8D) or hyperopia. * Patients with media opacity. * Patients with associated ocular pathology. * Patients with corneal topography not fitting to either treatment modalities.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Myopia, moderate are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Medicine, Fayoum University
Al Fayyum, Egypt